CO6960545A2 - Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retención de lágrimas - Google Patents

Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retención de lágrimas

Info

Publication number
CO6960545A2
CO6960545A2 CO14103881A CO14103881A CO6960545A2 CO 6960545 A2 CO6960545 A2 CO 6960545A2 CO 14103881 A CO14103881 A CO 14103881A CO 14103881 A CO14103881 A CO 14103881A CO 6960545 A2 CO6960545 A2 CO 6960545A2
Authority
CO
Colombia
Prior art keywords
rebamipide
medication
eye disease
retention agent
anterior eye
Prior art date
Application number
CO14103881A
Other languages
English (en)
Inventor
Yasuhiro Takeji
Hideo Nakashima
Hiroki Urashima
Hisashi Shinohara
Yuki Hirata
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6960545(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CO6960545A2 publication Critical patent/CO6960545A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO14103881A 2011-11-01 2014-05-14 Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retención de lágrimas CO6960545A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011240177 2011-11-01

Publications (1)

Publication Number Publication Date
CO6960545A2 true CO6960545A2 (es) 2014-05-30

Family

ID=47215697

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14103881A CO6960545A2 (es) 2011-11-01 2014-05-14 Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retención de lágrimas

Country Status (18)

Country Link
US (1) US20140294991A1 (es)
EP (1) EP2773350A1 (es)
JP (1) JP6060168B2 (es)
KR (1) KR101951511B1 (es)
CN (1) CN103945846A (es)
AR (1) AR088585A1 (es)
AU (1) AU2012333448A1 (es)
BR (1) BR112014010376A2 (es)
CA (1) CA2851095A1 (es)
CO (1) CO6960545A2 (es)
EA (1) EA201490721A1 (es)
HK (1) HK1198811A1 (es)
IL (1) IL231922A0 (es)
IN (1) IN2014CN03123A (es)
MX (1) MX2014005209A (es)
SG (1) SG11201401502TA (es)
TW (1) TW201322982A (es)
WO (1) WO2013065866A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081173B2 (ja) * 2011-12-12 2017-02-15 ロート製薬株式会社 眼科用水性組成物
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
KR20170039347A (ko) * 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
JPWO2020138135A1 (ja) 2018-12-26 2021-11-11 ライオン株式会社 眼科用組成物
WO2023054669A1 (ja) * 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084225A (ja) * 1983-10-17 1985-05-13 Hiroko Shimizu 点眼剤
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
AR004214A1 (es) 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
US8388995B1 (en) * 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
CN101534812B (zh) * 2006-12-11 2012-09-05 希格马托制药工业公司 L-卡尼汀制备用于治疗角膜疾病的滴眼剂形式药物的用途
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
CA2725487A1 (en) 2008-06-19 2009-12-23 Otsuka Pharmaceutical Co., Ltd. A pharmaceutical composition
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration

Also Published As

Publication number Publication date
AR088585A1 (es) 2014-06-18
JP2014532641A (ja) 2014-12-08
US20140294991A1 (en) 2014-10-02
HK1198811A1 (en) 2015-06-12
AU2012333448A1 (en) 2014-05-22
EA201490721A1 (ru) 2014-08-29
TW201322982A (zh) 2013-06-16
CA2851095A1 (en) 2013-05-10
SG11201401502TA (en) 2014-09-26
IL231922A0 (en) 2014-05-28
BR112014010376A2 (pt) 2017-04-25
CN103945846A (zh) 2014-07-23
WO2013065866A1 (en) 2013-05-10
JP6060168B2 (ja) 2017-01-11
MX2014005209A (es) 2014-05-28
IN2014CN03123A (es) 2015-07-03
KR101951511B1 (ko) 2019-02-22
EP2773350A1 (en) 2014-09-10
KR20140087030A (ko) 2014-07-08

Similar Documents

Publication Publication Date Title
CO6960545A2 (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retención de lágrimas
HK1203478A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
CL2014003619A1 (es) Jeringa prellenada que comprende una solución de un antagonista de vegf; empaque blister; uso de la jeringa para tratar enfermedades oculares.
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
HK1212380A1 (en) Compositions and methods for treating and preventing tissue injury and disease
HK1201196A1 (en) Treatment of ocular disease
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
IL236920B (en) Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
SG11201405028UA (en) Slowing myopia progression and/or the treatment or prevention of myopia or a disease or condition associated with myopia
EP2849749A4 (en) HISTATIN FOR HEALING CORNEAL WOUNDS AND EYE SURFACE DISEASES
HK1214526A1 (zh) 眼底疾病治療劑
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
HK1213824A1 (zh) 治療在糖尿病患者的血管疾病的方法
PT2959903T (pt) Medicamento para tratar doença ocular
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
EP3013425A4 (en) Treatment and diagnosis of ocular disease
BR112013009701A2 (pt) regimes de dosagem para o tratamento de doença vascular ocular
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
BR112013013636A2 (pt) processos para o tratamento de doenças da retina